Kidholm Kristian, Ølholm Anne Mette, Birk-Olsen Mette, Cicchetti Americo, Fure Brynjar, Halmesmäki Esa, Kahveci Rabia, Kiivet Raul-Allan, Wasserfallen Jean-Blaise, Wild Claudia, Sampietro-Colom Laura
Odense University Hospital, Department for Quality, Research and Health Technology Assessment, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Catholic University of the Sacred Heart, Department of Economics and Management and ALTEMS (Graduate School of Health Economics and Management), Largo F. Vito 1, 00168 Rome, Italy.
Health Policy. 2015 Nov;119(11):1424-32. doi: 10.1016/j.healthpol.2015.08.011. Epub 2015 Aug 24.
Assessments of new health technologies in Europe are often made at the hospital level. However, the guidelines for health technology assessment (HTA), e.g. the EUnetHTA Core Model, are produced by national HTA organizations and focus on decision-making at the national level. This paper describes the results of an interview study with European hospital managers about their need for information when deciding about investments in new treatments. The study is part of the AdHopHTA project. Face-to-face, structured interviews were conducted with 53 hospital managers from nine European countries. The hospital managers identified the clinical, economic, safety and organizational aspects of new treatments as being the most relevant for decision-making. With regard to economic aspects, the hospital managers typically had a narrower focus on budget impact and reimbursement. In addition to the information included in traditional HTAs, hospital managers sometimes needed information on the political and strategic aspects of new treatments, in particular the relationship between the treatment and the strategic goals of the hospital. If further studies are able to verify our results, guidelines for hospital-based HTA should be altered to reflect the information needs of hospital managers when deciding about investments in new treatments.
欧洲对新医疗技术的评估通常在医院层面进行。然而,卫生技术评估(HTA)指南,如欧盟卫生技术评估网络核心模型,是由各国的卫生技术评估组织制定的,且侧重于国家层面的决策。本文描述了一项针对欧洲医院管理人员的访谈研究结果,该研究围绕他们在决定是否投资新治疗方法时的信息需求展开。这项研究是AdHopHTA项目的一部分。研究人员与来自九个欧洲国家的53位医院管理人员进行了面对面的结构化访谈。医院管理人员认为新治疗方法的临床、经济、安全和组织方面与决策最为相关。在经济方面,医院管理人员通常更关注预算影响和报销情况。除了传统卫生技术评估中包含的信息外,医院管理人员有时还需要有关新治疗方法政治和战略方面的信息,特别是该治疗方法与医院战略目标之间的关系。如果进一步的研究能够验证我们的结果,那么基于医院的卫生技术评估指南应进行修改,以反映医院管理人员在决定是否投资新治疗方法时的信息需求。